Ursodeoxycholic acid CAS NO.128-13-2

Cholelithiasis dissolving drugs. It is mainly used for cholesterol-type gallstones that are not suitable for surgical treatment, especially floating cholesterol stones with basic normal gallbladder function, stone diameter below 15mm, X-ray, and non-calcified type. It also has a certain therapeutic effect on toxic hepatitis, cholecystitis, primary sclerosing cholangitis, and primary cholestatic cirrhosis. To mention the efficacy of Chemicalbook high-α-interferon in the treatment of chronic hepatitis C. There is diarrhea, rare constipation, allergic reactions, itching, headache, dizziness, stomach pain, pancreatitis and bradycardia. Patients with complete obstruction of the biliary tract and severe liver function and pregnant women are contraindicated. Use is suitable for the prevention and treatment of cholesterol gallstones, anionic detergent, anionic detergent, for biochemical research.

Xuzhou Maikai Biotechnology Co., Ltd. was established in November 2021 with a registered capital of 15 million yuan. It is an emerging R&D enterprise based on anti-tumor drugs and biotechnology. The company cooperates with Dalian University of Technology, Zhejiang University, Jinan University, etc. Colleges and universities have good cooperative relations. The founders and shareholders of the company have 20 years of working experience in the chemical industry. They have in-depth understanding and control of the product market. The technology is mature and advanced, and the product quality has reached the pharmaceutical level, which has been fully recognized by customers in the industry.

The company focuses on the biochemical industry, aspires to become the world's leading brand in this industry, and contributes to the cause of human health. Since its establishment, the company has always adhered to and adhered to the core business philosophy of "morality-based, honesty-first", and regards providing value to customers as our responsibility, which has won praise from customers.